Thus, a recent phase II trial with VC and carboplatin–paclitaxel on non-small-cell lung cancer found an improved tumor response rate, although the combination therapy could not overcome mutations in the Nrf-2-Keap I complex [172]. Here, NFE2L2 is linked to non-small cell lung carcinoma.